Versatile Functionalization of Ferritin Nanoparticles by Intein-Mediated Trans-Splicing for Antigen/Adjuvant Co-delivery
Source abstract
Abstract
Self-assembling protein nanoparticles are extensively and increasingly engineered to integrate adjuvants with antigens to elicit potent and long-term immunity due to uniform architecture, inherent biocompatibility, and excellent plasticity. However, functionalization of nanoparticles by surface tailoring has two common problems: (1) disassembly caused by loaded cargoes; and (2) an adjuvant that is inconvenient to co-deliver with an antigen by genetic fusion. Here, we report an intein-mediated trans-splicing approach that overcomes the detrimental effects of loaded proteins on ferritin nanoparticle stability and allows concurrent display of antigen and adjuvant in a facile, efficient, and site-specific manner. An immunization study with an epitope-based model antigen reveals that antigen and adjuvant co-delivery nanoparticles induce a more potent protective immunity than other formulations do. Our results demonstrate that protein engineering represents an intriguing approach for antigen/adjuvant co-delivery to potentiate antigen-associated immune responses.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Biochemical and Structural Characterization · Transgenic Plants and Applications · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Guangzhou Institute of Pediatrics, Department of Neonatology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 510623 Guangzhou, China
Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, 200031 Shanghai, China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · the Chinese Academy of Sciences ?100 Talents? program
References (38)
Show source-provided references
1. 10.3390/vaccines402001210.3390/vaccines4020012 ↗
2. 10.1016/j.bcp.2016.05.00110.1016/j.bcp.2016.05.001 ↗
3. 10.7150/ntno.1979610.7150/ntno.19796 ↗
4. 10.1038/nri286810.1038/nri2868 ↗
5. 10.1016/j.csbj.2015.11.00110.1016/j.csbj.2015.11.001 ↗
6. 10.3390/vaccines501000610.3390/vaccines5010006 ↗
7. 10.1016/j.coi.2007.04.00210.1016/j.coi.2007.04.002 ↗
8. 10.1080/14760584.2017.130644010.1080/14760584.2017.1306440 ↗
9. 10.1002/adma.20130098110.1002/adma.201300981 ↗
10. 10.1002/adma.20130058310.1002/adma.201300583 ↗
11. 10.1002/adma.20120077610.1002/adma.201200776 ↗
12. 10.1007/978-94-007-6552-8_2110.1007/978-94-007-6552-8_21 ↗
13. 10.1016/j.nano.2016.08.03010.1016/j.nano.2016.08.030 ↗
14. 10.1021/bm200369e10.1021/bm200369e ↗
15. 10.1002/bit.2563710.1002/bit.25637 ↗
16. 10.1021/acs.bioconjchem.7b0029610.1021/acs.bioconjchem.7b00296 ↗
17. 10.1021/acsnano.5b0368810.1021/acsnano.5b03688 ↗
18. 10.1038/srep2574110.1038/srep25741 ↗
19. 10.1021/acsnano.8b0280510.1021/acsnano.8b02805 ↗
20. 10.1038/srep1923410.1038/srep19234 ↗
21. 10.1002/smll.20180148810.1002/smll.201801488 ↗
22. 10.1186/s12951-016-0181-110.1186/s12951-016-0181-1 ↗
23. 10.1007/s10529-015-1905-210.1007/s10529-015-1905-2 ↗
24. 10.1002/smll.20100109510.1002/smll.201001095 ↗
25. 10.1016/j.nbt.2014.12.00610.1016/j.nbt.2014.12.006 ↗
26. 10.1107/S139900471501307310.1107/S1399004715013073 ↗
27. 10.1074/jbc.M112.37268010.1074/jbc.M112.372680 ↗
28. 10.1016/j.pep.2016.04.00210.1016/j.pep.2016.04.002 ↗
29. 10.1128/JVI.01848-1310.1128/JVI.01848-13 ↗
30. 10.1186/s12967-017-1152-510.1186/s12967-017-1152-5 ↗
31. 10.1002/anie.20151088510.1002/anie.201510885 ↗
32. 10.1016/j.addr.2008.12.01310.1016/j.addr.2008.12.013 ↗
33. 10.1126/science.115498610.1126/science.1154986 ↗
34. 10.1177/204993611771359310.1177/2049936117713593 ↗
35. 10.1038/nm.392710.1038/nm.3927 ↗
36. 10.3389/fimmu.2018.0143210.3389/fimmu.2018.01432 ↗
37. 10.1016/j.jmb.2013.10.02110.1016/j.jmb.2013.10.021 ↗
38. 10.1073/pnas.111548510910.1073/pnas.1115485109 ↗